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Two Zn(II) complexes with the condensation product of 2-quinolinecarboxaldehyde and 
trimethylammonium acetohydrazide chloride (Girard's T reagent) (HLCl) and monodentate 
pseudohalides (azide and cyanate) have been synthesized and characterized by elemental 
analysis, IR and NMR spectroscopy and single-crystal X-ray diffraction. In both complexes, the 
coordination surroundings of the Zn(II) ions consist of a deprotonated hydrazone ligand 
coordinated through an NNO set of donor atoms and two monodentate pseudohalides (N3– or 
NCO–) at the remaining coordination sites. The Zn(II) complexes showed low to moderate 
activity against laboratory control strains of pathogenic bacteria and fungi.
Keywords: Zn(II) complexes; Hydrazones; Crystal structure; Antimicrobial activity; 
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21. Introduction
Pseudohalides (azide and cyanate) are versatile ligands which can be coordinated as monodentate 
species [1-3] or as bridges between metal centers [4-7]. The homoatomic azido ligand exhibits 
many bridging coordination modes: single and double μ1,3-N3 (end-to-end, EE) and μ1,1-N3 
(end-on, EO), μ1,1,3-N3, μ1,1,1-N3, μ1,1,1,1-N3, μ1,1,2,2-N3, and μ1,1,1,3,3,3-N3 [8]. Cyanate as an 
ambidentate ligand exhibits linkage isomerism and may coordinate through nitrogen or oxygen 
donor atoms as a monodentate or bridging ligand (end-on μ1,1-κN and μ1,1-κO or end-to-end μ1,3) 
[9]. Zinc naturally occurs as the non-redox active divalent cation Zn(II). Due to its d10 electronic 
configuration, the Zn(II) ion has a zero ligand field stabilization energy, so the bonding energies 
and repulsions among the ligands determine the coordination geometry in its complexes [10]. 
Pseudohalide Zn(II) complexes attract attention due to their structural and luminescent properties 
[11-14]. Zinc, as one of the most important bio-elements, takes a significant part in metabolic 
pathways and regulation of gene expression [15]. A low concentration of Zn(II) ion is necessary 
for normal metabolism of bacteria, while at high concentration Zn(II) inhibits bacterial growth 
[16]. Schiff base complexes containing a quinoline pharmacophore showed significant antitumor 
and antimicrobial activity [17-21]. As a part of our investigations of hydrazone metal complexes 
with pseudohalide ligands [3, 22-28], we have previously synthesized and characterized a 
dinuclear end-on azido bridged Ni(II) complex with the condensation product of 
2-quinolinecarboxaldehyde and trimethylammonium acetohydrazide chloride (Girard's T 
reagent) (HLCl) [29]. In this study we extend our work to examine reactions of Zn(II) with the 
HLCl ligand and pseudohalides (azide and cyanate). The mononuclear azido and isocyanato 
Zn(II) complexes obtained, i.e. [ZnL(N3)2] (1) and [ZnL(NCO)2] (2), were structurally 
characterized and their antimicrobial activity was tested.
2. Experimental
2.1. Materials and methods
2-Quinolinecarboxaldehyde (97%) and Girard’s T reagent (99%) were obtained from Aldrich. IR 
spectra were recorded on a Nicolet 6700 FT-IR spectrometer using the ATR technique in the 
region 4000−400 cm−1 (s-strong, m-medium, w-weak). 1H (500 MHz), 13C (125 MHz) and 2-D 
NMR spectra of ligand HLCl and Zn(II) complexes were recorded on a Bruker Avance 500 
spectrometer at room temperature using TMS as internal standard in methanol−d4 in the case of 
3HLCl and DMSO−d6 in the case of Zn(II) complexes. Chemical shifts are expressed in ppm (δ) 
values and coupling constants (J) in Hz. Elemental analyses (C, H, and N) were performed by 
standard micro-methods using the ELEMENTARVario ELIII C.H.N.S.O analyzer.
2.2. Synthesis
2.2.1. Synthesis of (E)-N,N,N-trimethyl-2-oxo-2-(2-(quinolin-2-
ylmethylene)hydrazinyl)ethan-1-aminium chloride (HLCl). The ligand HLCl was 
synthesized in the reaction of 2-quinolinecarboxaldehyde and Girard’s T reagent according to the 
previously described method [29]. IR and NMR spectra of HLCl are given in the Supplementary 
Material.
2.2.2. Synthesis of diazido (E)-N,N,N-trimethyl-2-oxo-2-(2-(quinolin-2-
ylmethylene)hydrazinyl)ethan-1-aminium zinc(II) complex ([ZnL(N3)2]) (1). The ligand 
HLCl (92.0 mg, 0.30 mmol) was dissolved in methanol (30 mL) and solid Zn(BF4)2·6H2O (104.1 
mg, 0.30 mmol) was added. After complete dissolution of Zn(BF4)2·6H2O in the reaction 
mixture, NaN3 (39.0 mg, 0.60 mmol) was added. The reaction solution was stirred at room 
temperature for 4 h. After slow evaporation of solvent in a refrigerator (~ 4 C) for 48 h, yellow 
crystals were obtained. Yield 39.7 mg (32%). Elemental analysis calcd for C15H18N10OZn: C 
42.92 %, H 4.32 %, N 33.37 %, found: C 43.03 %, H 4.56 %, N 33.35 %.
IR (cm–1): 3310 (w), 3027 (w), 2939 (w), 2817 (w), 2169 (w), 2067 (s), 1923 (w), 
1748 (w), 1645 (w), 1612 (w), 1566 (s), 1535 (s), 1398 (m), 1344 (w), 1300 (s), 1232 (w), 
1125 (w), 1086 (s), 1032 (w), 972 (w), 925 (m), 873 (w), 833 (w), 785 (w), 757 (m), 632 (w), 
589 (w). 1H NMR (500 MHz, DMSO−d6), (numbering of atoms according to scheme 1), δ (ppm) 
3.28 (s, 9H, C12-H), 4.17 (s, 2H, C11-H), 8.38 (s, 1H, C9-H), 7.71 (d, 1H, 3JC3-H/C4-H = 10 Hz, 
C3-H), 8.09 (d, 1H, 3JC3-H/C4-H = 10 Hz, C4-H), 8.70 (d, 1H, 3JC5-H/C6-H = 10 Hz, C5-H), 7.91(m, 
1H, C6-H), 7.91 (m, 1H, C7-H), 8.70 (d, 1H, 3JC7-H/C8-H = 10 Hz, C8-H). 13C NMR (125 MHz, 
DMSO−d6), (numbering of atoms according to scheme 1), δ (ppm) 53.5 (C12), 66.4 (C11), 
128.04 (C9), 148.9 (C2), 128.3 (C3), 128.6 (C4), 129.3 (C4a), 140.5 (C5), 122.5 (C6), 131.7 
(C7), 143.6 (C8), 145.4 (C8a), 172.5 (C10).
2.2.3. Synthesis of diisocyanato (E)-N,N,N-trimethyl-2-oxo-2-(2-(quinolin-2-
4ylmethylene)hydrazinyl)ethan-1-aminium zinc(II) complex ([ZnL(NCO)2]) (2). To a solution 
of HLCl (92.0 mg, 0.30 mmol) in methanol (30 mL), solid Zn(BF4)2·6H2O (104.1 mg, 
0.30 mmol) was added. After complete dissolution of the zinc(II) salt in the reaction solution, 
NaOCN (78.0 mg, 1.20 mmol) was added. The reaction mixture was stirred for 3 h at room 
temperature. After slow evaporation of solvent in a refrigerator (~ 4 C) for 48 h, yellow crystals 
were obtained. Yield 71.2 mg (56%). Elemental analysis calcd for C17H18N6O3Zn: C 48.64 %, H 
4.32 %, 20.02 N %, found: C 48.73 %, H 4.47 %, N 19.98 %.
IR (cm–1): 3536 (w), 3063 (w), 2966 (w), 2203 (s), 1611 (w), 1563 (m), 1530 (s), 
1482 (w), 1400 (w), 1343 (w), 1305 (w), 1242 (w), 1203 (w), 1124 (w), 1080 (w), 1026 (w), 
995 (w), 972 (w), 931 (w), 830 (w), 807 (w), 785 (w), 752 (w), 629 (w). 1H NMR (500 MHz, 
DMSO−d6), (numbering of atoms according to scheme 1), δ (ppm) 3.27 (s, 9H, C12-H), 4.15 (s, 
2H, C11-H), 8.34 (s, 1H, C9-H), 7.71 (d, 1H, 3JC3-H/C4-H = 10 Hz, C3-H), 8.09 (d, 1H, 3JC3-H/C4-H 
= 10 Hz, C4-H), 8.66 (d, 1H, 3JC5-H/C6-H =10 Hz, C5-H), 7.91 (m, 1H, C6-H), 7.91 (m, 1H, 
C7-H), 8.66 (d, 1H, 3JC7-H/C8-H =10 Hz, C8-H). 13C NMR (125 MHz, DMSO−d6), (numbering of 
atoms according to scheme 1), δ (ppm) 53.5 (C12), 66.3 (C11), 127.5 (C9), 149.0 (C2), 
127.9 (C3), 128.4 (C4), 125.4 (C4a), 140.0 (C5), 122.4 (C6), 131.7 (C7), 144.0 (C8), 
145.5 (C8a), 172.3 (C10), 129.1 (OCN−).
2.3. Crystallographic structure determination
The molecular structures of 1 and 2 were determined by single-crystal X-ray diffraction methods. 
Crystallographic data and refinement parameters of 1 and 2 are listed in table 1. The X‒ray 
intensity data for all complexes were collected at room temperature with a Nonius Kappa CCD 
diffractometer with graphite-monochromated Mo‒Kα radiation (λ = 0.71073 Å). The data were 
processed using DENZO-SMN [30]. The structures were solved by direct methods using SIR-92 
[31] and refined by full-matrix least-squares based on F2 with SHELXL-97 [32]. All non-
hydrogen atoms were refined anisotropically. Hydrogens bonded to C9 in both structures were 
visible in the last stages of the refinement and were refined with the distance restraints (DFIX) 
with C–H = 0.98 Å and isotropic thermal parameters (1.2 times the thermal parameter of the 
attached carbon atom). All other C–H hydrogen atoms were included in the model at 
geometrically calculated positions and refined using a riding model. ORTEP-3 for Windows was 
used to prepare drawings [33]. Crystallographic data for the structures have been deposited at the 
5Cambridge Crystallographic Data Centre as supplementary publication CCDC 1546080 and 
1546081 for 1 and 2, respectively. Copies of the structures can be obtained free of charge at 
www.ccdc.cam.ac.uk/data_request/cif.
2.4. Antimicrobial activity
Antimicrobial activity was investigated against eight laboratory control strains of bacteria i.e., 
Gram-positive: Staphylococcus aureus (ATCC 6538), Enterococcus faecalis (ATCC 29212), 
Bacillus subtilis (ATCC 6633); Gram-negative: Escherichia coli (ATCC 10536), Klebsiella 
pneumoniae (ATCC 13883), Pseudomonas aeruginosa (ATCC 9027), and Salmonella enterica 
subsp. abony (ATCC 6017) and one strain of yeast Candida albicans (ATCC 10231). In order to 
determine minimum inhibitory concentrations (MIC) of the tested compounds, a broth 
microdilution method was used according to Clinical and Laboratory Standards Institute 
guidelines CLSI (2016) [34] with some modifications. Tests were performed in Müller-Hinton 
broth for the bacterial strains and in Sabouraud dextrose broth for Candida albicans. The tested 
compounds were dissolved in 1% dimethyl sulfoxide (DMSO) and then diluted to the highest 
concentration. Twofold serial concentrations of the compounds were prepared in a 96-well 
microtiter plate (ranging from 62.5–1000 µg/mL) with addition of 0.05% 2,3,5-triphenyl-2H-
tetrazolium chloride (TTC, Sigma-Aldrich, USA) as a growth indicator. All of the MIC 
determinations were performed in duplicate, and two positive growth controls were included 
(wells containing only the microorganisms in the broth). Each test was repeated three times. 
Identical MIC values were obtained in all experiments for a particular substance and strain.
3. Results and discussion
3.1. Synthesis
The ligand (E)-N,N,N-trimethyl-2-oxo-2-(2-(quinolin-2-ylmethylene)hydrazinyl)ethan-1-
aminium chloride (HLCl) was synthesized in the reaction of 2-quinolinecarboxaldehyde and 
Girard’s T reagent as described previously [29] and used for the synthesis of complexes 
[ZnL(N3)2] (1) and [ZnL(NCO)2] (2) (scheme 1). Complex 1 was obtained in the reaction of 
HLCl with Zn(BF4)2·6H2O and NaN3 in the molar ratio 1 : 1 : 2 in methanol. Reaction of HLCl 
with Zn(BF4)2·6H2O and NaOCN in the molar ratio 1 : 1 : 4 in methanol results in formation of 
2. In both complexes, the hydrazone ligand is coordinated in the deprotonated formally neutral, 
6zwitterionic form. Deprotonation of the ligand was facilitated by the presence of basic OCN− and 
N3− anions in the reaction solution. In 1 and 2, Zn(II) is five coordinate with quinoline nitrogen, 
azomethine nitrogen and carbonyl oxygen atoms from hydrazone ligands and two N-coordinated 
monodentate pseudohalide ligands.
3.2. Spectroscopy
3.2.1. IR spectra. IR spectra of 1 and 2 confirm coordination of the HLCl ligand in the 
deprotonated α-oxyazine form. The new band at 1535 cm−1 in the spectrum of 1 and at 
1530 cm−1 in the spectrum of 2, corresponding to ν(−O–C=N) vibration of the deprotonated 
hydrazine moiety, appeared instead of the band of carbonyl group of non-coordinated hydrazonic 
form of HLCl at 1699 cm−1. In the IR spectrum of 1 a strong band at 2067 cm−1 corresponds to 
the vibration of coordinated azide ions. Coordination of cyanate ions in 2 was confirmed from 
the appearance of a strong band at 2203 cm−1 [35].
3.2.2. NMR spectra. The signal of a hydrazide NH is not observed in the 1H NMR spectra of 1 
and 2, indicating that the ligand is coordinated in the deprotonated zwitterionic form. 
Coordination of the azomethine nitrogen in 1 and 2 can be confirmed from the position of the 
signal of proton C9-H (8.38 ppm in 1, 8.34 ppm in 2), which is shifted downfield in comparison 
with the corresponding signal in HLCl at 8.17 ppm. The downfield shift of the carbonyl carbon 
(C10) from 167.0 ppm in the spectrum of HLCl to 172.5 ppm and 172.3 ppm in the spectra of 1 
and 2, respectively, indicates coordination of the carbonyl oxygen atom. Coordination of the 
quinoline nitrogen atom results in the upfield shift of the C2 atom signal from 154.4 ppm in the 
spectrum of HLCl to 148.9 ppm and 149.0 ppm in the spectra of 1 and 2, respectively. The 
signal of the azomethine carbon atom (C9) at 146.9 ppm in the spectrum of HLCl is shifted 
upfield in the spectra of 1 and 2 (127.5 ppm in spectrum of 1 and 128.0 in the spectrum of 2). In 
the 13C NMR spectrum of 2 the signal of a coordinated OCN− ion was observed at 129.1 ppm 
which is in accord with the previously published 13C NMR results for isocyanato complexes of 
Zn(II) [36].
3.3. Description of the crystal structures
Compounds 1 and 2 crystallize in the same space group P21/c with almost the same lattice 
7parameters. The structures of both compounds are displayed in figures 1 and 2, respectively. 
Selected bond lengths and angles of 1 and 2 are given in table 2. The zinc(II) central ion is 
coordinated with a tridentate ligand L and with two N3– ligands in the case of 1 and two NCO– 
ligands in the case of 2. The tridentate ligand L is coordinated to the zinc ion with a NNO set of 
donor atoms forming two five-membered chelate rings. The largest deviation from the best plane 
that contained the condensed five-membered chelate rings is found for the carboxyl O1 atom in 
both 1 and 2. The values are 0.08840(21) Å and 0.1197(15) Å out of the plane for 1 and 2, 
respectively.
For five-coordinate complexes, the angular structural parameter () is used to describe the 
degree of trigonality, within the structural continuum between trigonal bipyramidal and square 
based pyramidal geometry. The value of  is defined by an equation represented by  = 
(  )/60, where  is the greatest basal angle and  is the second greatest angle;  is 0 for 
regular square based pyramidal geometry and 1 for regular trigonal bipyramidal geometry [37]. 
The  values for 1 and 2 of 0.31 and 0.34, respectively, indicate that the Zn(II) ion has a distorted 
square based pyramidal coordination geometry. In 1 and 2, the Zn(II) ion is lifted out of the 
plane of the four in-plane ligand atoms (N1, N2, N5 and O1) by a distance  of 0.6165(5) and 
0.6462(4) Å, respectively (table 3). The angular structural parameters () of 1 and 2 have been 
compared with those of structurally related five-coordinate Zn(II) complexes with Schiff base 
ligands (table 3). In complexes 3-8 [38-42], Schiff base ligands are coordinated to Zn(II) ion 
through an NNO set of donor atoms forming two fused five-membered chelate rings. The other 
two coordination sites are supplemented by monodentate ligands (Cl, Br or DMSO). All five-
coordinate Zn(II) complexes which have been considered here adopt a distorted square based 
pyramidal coordination geometry, as indicated by  values ranging from 0.13 to 0.40. The 
greatest trigonal distortion from the square based pyramidal coordination geometry was observed 
for 3 [38] in which two coordination sites are occupied by Cl anions. For this complex the 
parameter  is 0.40. The smallest parameter  of 0.13 is calculated for 8 [41] which also includes 
two Cl anions in the coordination sphere. In 1-8, the greatest basal angle (), that is, 
NheteroaromaticZnOamide spans the range from 143.18(9) to 149.56(7), while the second greatest 
angle (), that is, NimineZnX (X = monodentate ligand) covers the range from 123.36(5) to 
135.35(8).
8In the crystal structures of 1 and 2, quinoline rings are involved in intermolecular  
interactions around the center of inversion at ½, 0, ½. The distances between the centers of 
gravity of the pyridine fragments are 3.381(2) and 3.420(2) Å, with a slippage of 0.553 and 
0.655 Å, for 1 and 2, respectively. The centers of gravity of pyridine and arene fragments are 
separated by 4.089(3) and 3.980(2) Å in 1 and 2, respectively.
3.4. Antimicrobial activity
In vitro antimicrobial activity of HLCl ligand, Zn(II) complexes 1 and 2, and previously reported 
dinuclear azido bridged Ni(II) complex with HLCl [29], was examined against laboratory 
control strains of Gram-positive and Gram-negative bacteria and one strain of yeast C. albicans. 
The results (table 4) indicated that the investigated complexes were less active than the standard 
drugs. The dinuclear azido bridged Ni(II) complex with HLCl was inactive against the tested 
bacterial strains and showed activity only against C. albicans (MIC value 0.571 mM). HLCl 
showed noteworthy activity only against E. faecalis. Complexes 1 and 2 showed low to moderate 
antimicrobial activity. The best activity of 1 and 2 was observed against B. subtilis and 
K. pneumoniae (0.148 mM). Complex 2 showed better activity than 1 against most of the tested 
microbial strains. With the exception of the case of S. aureus, the activity of 2 was better than the 
activity of Zn(II) salt, NaOCN and HLCl. A literature survey shows that complexation with 
ligands frequently improves antimicrobial activity of Zn(II) ion. Previously reported results 
indicate that antimicrobial activity of Zn(II) complexes depends on their liphophilicity, stability, 
steric and electronic properties, which are determined by the nature of coordinated ligand 
[28, 43-45].
4. Conclusion
The synthesized Zn(II) complexes contain a common tridentate ligand, the condensation product 
of 2-quinolinecarboxaldehyde and trimethylammonium acetohydrazide chloride (Girard's T 
reagent), coordinated in the deprotonated zwitterionic form via quinoline nitrogen, imine 
nitrogen and carbonyl oxygen atoms and two monodentate pseudohalides (azide or cyanate) in 
the remaining two coordination sites. The investigated Zn(II) complexes showed low to 
moderate antimicrobial activity against a range of Gram-positive and Gram-negative bacteria and 
one strain of yeast C. albicans.
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Table 1. Crystal data and structure refinement details for 1 and 2.
1 2
Formula C15H18N10OZn C17H18N6O3Zn
Fw (g mol–1) 419.76 419.74
Crystal size (mm) 0.20  0.10  0.05 0.10  0.10  0.05
Crystal color Yellow Yellow
Crystal system Monoclinic Monoclinic
Space group P21/c P21/c
a (Å) 7.9427(2) 8.2977(2)
b (Å) 22.0751(9) 21.6627(4)
c (Å) 10.7922(4) 10.8121(3)
β () 98.681(2) 99.1360(10)
V (Å3) 1870.58(11) 1918.83(8)
Z 4 4
Calcd density (g cm-3) 1.491 1.453
F(000) 864 864
No. of collected reflns 8122 8342
No. of independent reflns 4206 4363
Rint 0.0194 0.0332
No. of reflns observed 2773 2699
No. parameters 250 250
R[I > 2σ (I)]a 0.0549 0.0434
wR2 (all data)b 0.1753 0.1090
Goof, S c 1.030 1.017
Max/min residual electron density (e Å–3) +0.86/–0.52 +0.26/–0.24
a R = ∑||Fo| – |Fc||/∑|Fo|;
b wR2 = {∑[w(Fo2 – Fc2)2]/∑[w(Fo2)2]}1/2;
c S = {∑[(Fo2 – Fc2)2]/(n/p}1/2, where n is the number of reflections and p is the total number of 
parameters refined.
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Table 2. Selected bond lengths (Å) and angles (°) for 1 and 2.
1 2
Zn1–N1 2.298(4) Zn1–N1 2.344(2)
Zn1–N2 2.049(3) Zn1–N2 2.051(2)
Zn1–N5 1.975(4) Zn1–N5 1.931(2)
Zn1–N8 1.982(5) Zn1–N6 1.935(3)
Zn1–O1 2.204(3) Zn1–O1 2.197(2)
N2–N3 1.369(4) N2–N3 1.380(3)
N2–C9 1.265(5) N2–C9 1.274(3)
O1–Zn1–N1 147.68(10) O1–Zn1–N1 146.98(8)
O1–Zn1–N2 73.47(11) O1–Zn1–N2 73.79(8)
O1–Zn1–N5 98.70(15) O1–Zn1–N5 100.60(9)
O1–Zn1–N8 98.8(2) O1–Zn1–N6 98.32(12)
N5–Zn1–N8 111.9(2) N5–Zn1–N6 117.64(13)
N5–N6–N7 176.3(4) N5–C15–O2 178.2(4)
N8–N9–N10 173.0(8) N6–C16–O3 176.4(5)
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Table 3. Structural parameters correlating coordination geometry of structurally related five-coordinated 
Zn(II) complexes.
Complex  ()  ()   (Å) References
[ZnL(N3)2] (1) 147.68(10) 129.4(2) 0.31 0.6165(5) This work
[ZnL(NCO)2] (2) 146.98(8) 126.41(10) 0.34 0.6462(4) This work
[Zn(L2)Cl2]0.5H2Oa (3) 147.07(6) 123.36(5) 0.40 0.6453(3) [38] 
[Zn(L3)Cl2]b (4) 146.03(7) 126.09(5) 0.33  0.6715(2) [39] 
[Zn(L4)Br2]c (5) 146.06(9) 129.81(8) 0.27 0.6677(4) [40] 
[Zn(L5)Cl(DMSO)]d (6) 149.56(7) 134.73(6) 0.25 0.5025(3) [41]
[Zn(L6)Cl2]e (7) 144.88(7) 133.36(6) 0.19 0.6438(3) [42] 
[Zn(L7)Cl2]f (8) 143.18(9) 135.35(8) 0.13 0.6503(4) [41] 
a L2 = 2-hydroxyimino-N'-[1-(2-pyridyl)ethylidene]propanohydrazide; 
b L3 = (E)-4-(dimethylamino)-N′-(pyridin-2-ylmethylene)benzohydrazide; 
c L4 = di-2-pyridyl ketone N4-phenyl-3-semicarbazone; 
d L5 = 2-formylpyridine-para-nitro-phenyl hydrazone; 
e L6 = 2-formylpyridine isonicotinoyl hydrazone;
f L7 = 2-formylpyridine-para-chloro-phenyl hydrazone
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Table 4. Antimicrobial activity of investigated compounds.
MIC (mM)
Microorga
nisms HLC
l
Zn(BF4)2·6
H2O
Na
N3
NaO
CN 1 2
meropen
em*
amikac
in*
ampicill
in*
amphoteri
cin*
S. aureus
ATCC 
6538
1.63
0 0.180
3.8
46
>15.3
85
1.1
91
0.2
97 0.004 0.005 0.008 n.t.
E. faecalis
ATCC 
29212
0.40
7 0.360
0.9
61
15.38
5
1.1
91
0.2
97 0.003 0.005 0.002 n.t.
B. subtilis
ATCC 
6633
3.26
0 0.360
0.9
61
>15.3
85
0.1
48
0.1
48 0.005 n.t. 0.003 n.t.
E. coli
ATCC 
10536
>3.2
60 2.881
3.8
46
>15.3
85
0.2
97
0.1
48 0.006 0.004 0.010 n.t.
K. 
pneumonia
e
ATCC1388
3
1.63
0 1.440
1.9
23
>15.3
85
0.1
48
0.1
48 0.008 0.006 0.012 n.t.
P. 
aeruginosa
ATCC 
9027
˃3.26
0
>2.881 7.692
>15.3
85
1.1
91
2.3
82 0.010 0.009 n.t. n.t.
S. enterica
ATCC 
6017
˃3.26
0
0.720 3.846
>15.3
85
1.1
91
0.2
97 0.006 0.008 0.014 n.t.
C. albicans
ATCC 
10231
˃3.26
0
>2.881 0.961
>15.3
85
1.1
91
0.2
97 n.t. n.t. n.t. 0.0005
n.t. not tested
* reference antimicrobial drugs
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